A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma.

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano. A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma. Blood. 2022 Nov 15; 140(Supplement 1):11954-11955.

2022
https://researcherprofiles.org/profile/420601060

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano